# Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

> **NCT00767520** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 155 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Exemestane + Dasatinib
- **DRUG:** Exemestane + Placebo

## Key facts

- **NCT ID:** NCT00767520
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2011-03
- **Final completion:** 2012-12
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2013-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00767520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00767520, "Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00767520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*